These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86 related articles for article (PubMed ID: 15320361)
1. The development of injectable biologic agents. Rich SJ J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S3. PubMed ID: 15320361 [No Abstract] [Full Text] [Related]
2. Management of moderate to severe plaque psoriasis with biologic therapy. Pariser DM Manag Care; 2003 Apr; 12(4):36-44. PubMed ID: 12747028 [No Abstract] [Full Text] [Related]
3. Considerations for assessing the cost of biologic agents in the treatment of psoriasis. Rich SJ J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S38-41. PubMed ID: 15253689 [TBL] [Abstract][Full Text] [Related]
4. Clinical update on alefacept: consideration for use in patients with psoriasis. Gade JN J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S33-7. PubMed ID: 15253688 [TBL] [Abstract][Full Text] [Related]
5. Treatment of palmoplantar psoriasis with intramuscular alefacept. Myers W; Christiansen L; Gottlieb AB J Am Acad Dermatol; 2005 Aug; 53(2 Suppl 1):S127-9. PubMed ID: 16021161 [TBL] [Abstract][Full Text] [Related]
6. New treatments for psoriasis: which biologic is best? Nelson AA; Pearce DJ; Fleischer AB; Balkrishnan R; Feldman SR J Dermatolog Treat; 2006; 17(2):96-107. PubMed ID: 16766334 [TBL] [Abstract][Full Text] [Related]
7. Alefacept treatment for chronic plaque psoriasis. Dunn LK; Feldman SR Skin Therapy Lett; 2010 Apr; 15(4):1-3. PubMed ID: 20361167 [TBL] [Abstract][Full Text] [Related]
8. Immunobiologic agents for the treatment of psoriasis: clinical research delivers new hope for patients with psoriasis. Gottlieb A Arch Dermatol; 2003 Jun; 139(6):791-3. PubMed ID: 12810512 [No Abstract] [Full Text] [Related]
9. Biologic agents in psoriasis. Lee MR; Cooper AJ Australas J Dermatol; 2006 Nov; 47(4):217-29; quiz 229-30. PubMed ID: 17034462 [TBL] [Abstract][Full Text] [Related]
11. Alefacept: a novel and selective biologic agent for the treatment of chronic plaque psoriasis. Ortonne JP; Prinz JC Eur J Dermatol; 2004; 14(1):41-5. PubMed ID: 14965795 [TBL] [Abstract][Full Text] [Related]
12. The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients. Young MS; Horn EJ; Cather JC Expert Rev Clin Immunol; 2011 Jan; 7(1):9-13. PubMed ID: 21162644 [TBL] [Abstract][Full Text] [Related]
13. Alefacept (Amevive) for treatment of psoriasis. Med Lett Drugs Ther; 2003 Apr; 45(1154):31-2. PubMed ID: 12717339 [No Abstract] [Full Text] [Related]
14. Severe exacerbation of psoriasis after intravenous immunoglobulin in patient with multiple sclerosis that started during biologic therapy. Ettler J; Arenberger P; Arenbergerova M; Gkalpakiotis S J Eur Acad Dermatol Venereol; 2016 Feb; 30(2):355-6. PubMed ID: 25327640 [No Abstract] [Full Text] [Related]
16. First biologic treatment approved for psoriasis. FDA Consum; 2003; 37(3):4. PubMed ID: 12793376 [No Abstract] [Full Text] [Related]
17. On multiple courses of alefacept. Leonardi CL; Strober BE J Am Acad Dermatol; 2006 Nov; 55(5):916-7. PubMed ID: 17052512 [No Abstract] [Full Text] [Related]
18. Combining systemic retinoids with biologic agents for moderate to severe psoriasis. Smith EC; Riddle C; Menter MA; Lebwohl M Int J Dermatol; 2008 May; 47(5):514-8. PubMed ID: 18412874 [TBL] [Abstract][Full Text] [Related]